MDGL — Madrigal Pharmaceuticals Balance Sheet
0.000.00%
Last trade - 00:00
- $4.45bn
- $3.93bn
- 43
- 13
- 76
- 40
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | — | — | — | — | — |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Cash | |||||
Cash and Equivalents | |||||
Short Term Investments | |||||
Cash and Short Term Investments | 439 | 284 | 270 | 359 | 634 |
Prepaid Expenses | |||||
Total Current Assets | 440 | 285 | 272 | 361 | 637 |
Net Property, Plant And Equipment | 1.86 | 1.83 | 1.65 | 1.2 | 3.27 |
Total Assets | 442 | 287 | 273 | 363 | 641 |
Accounts Payable | |||||
Accrued Expenses | |||||
Notes Payable / Short Term Debt | |||||
Total Current Liabilities | 25.1 | 46.6 | 76.8 | 116 | 119 |
Long Term Debt | |||||
Total Long Term Debt | |||||
Total Debt | |||||
Total Other Liabilities | |||||
Total Liabilities | 25.5 | 47 | 77.2 | 165 | 235 |
Non Redeemable Preferred Stock | |||||
Common Stock | |||||
Additional Paid In Capital | |||||
Retained Earnings (Accumulated Deficit) | |||||
Other Equity | |||||
Total Equity | 417 | 240 | 196 | 197 | 405 |
Total Liabilities & Shareholders' Equity | 442 | 287 | 273 | 363 | 641 |
Total Common Shares Outstanding |